Conclusion
castrate-resistant prostate cancer
METASTATIC PROSTATE CANCER, CASTRATE-RESISTANT PROSTATE CANCER
In conclusion, the addition of avelumab to NHT did not demonstrate clinical activity in Black men with new mCRPC. The unexpected short interval between PSA and radiographic and/or clinical progression observed in this study has potential clinical implications.ClinicalTrials.gov Identifier: NCT03770455 (IND number 139559).Previous studies have shown the benefit of immune-based therapies, such as sipuleucel-T, for Black men with metastatic prostate cancer. This study explored the efficacy of the PD-L1 inhibitor avelumab in Black men with metastatic castrate-resistant prostate cancer progressing after abiraterone or enzalutamide.